

Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors

Andrew A. Davis¹, Wade T. lams², David Chan³, Michael S. Oh¹, Robert W. Lentz¹, Rohith Srivas⁴, Nicole Lambert⁴, Alex Robertson⁴, Neil Peterman⁴, Abhik Shah⁴, Timothy Wilson⁴, Jason Close⁴, Peter George⁴, Haleigh Wood⁴, Ayse Tezcan⁴, Ram Yalamanchili⁴, Ken Nesmith⁴, John C. Spinosa⁴, Haluk Tezcan^{4,#}, Young Kwang Chae^{1,#}

patients undergoing treatment for advanced-stage solid tumors.

survival (PFS).

clinical evaluation by a median of 34 days.





¹Feinberg School of Medicine, Northwestern University, Chicago, IL, ²Vanderbilt University Medical Center, Nashville, TN ³Cancer Care Associates TMPN, Redondo Beach, CA, ⁴Lexent Bio, Inc., San Francisco & San Diego, CA, [#]Questions can be addressed to either htezcan@lexentbio.com or ychae@nm.org

Robert H. Lurie Comprehensive Cancer Center OF NORTHWESTERN UNIVERSITY

attended investigator meeting (EMD Serono). YKC has Foundation Medicine, Counsyl, Neogenomics, Guardan